首页|Meningeal lymphatic vasculature,a general target for glioblastoma therapy?

Meningeal lymphatic vasculature,a general target for glioblastoma therapy?

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Glioblastoma(GBM)causes nearly universal mortality as a result of the failure of conventional therapies includ-ing surgical resection,targeted radiation therapy,and chemotherapy.An increasingly important treatment option is combining immunotherapy with other therapies in both preclinical and clinical studies.The central nervous system(CNS)has been historically considered an immune privileged area,but increasing evidence,including the recent rediscovery of meningeal lymphatic vessels(MLVs),has overturned this notion.MLVs are populated by multiple immune cells and connect the CNS to the periphery by draining cerebrospinal fluid with soluble CNS antigens and immune cells into cervical lymph nodes.In the past few years,more and more studies have indicated that MLVs are involved in the regulation of inflammation and the immune response in the pathogenesis of var-ious CNS diseases including GBM.Here,we explore the critical interlinkages between MLVs and GBM therapies including chemotherapy,radiotherapy and immunotherapy,and propose the meningeal lymphatic vasculature as a general target for GBM therapy.

Meningeal lymphatic vesselsGlioblastomaImmunityVascular endothelial growth factor CImmune modulation

Changping Zhou、Han Xu、Jincai Luo

展开 >

Laboratory of Vascular Biology,Institute of Molecular Medicine,College of Future Technology,Beijing Key Laboratory of Cardiometabolic Molecular Medicine,Peking University,Beijing 100871,China

国家自然科学基金国家自然科学基金国家自然科学基金国家重点研发计划Peking-Tsinghua Center for Life Sciences中国博士后科学基金

8193001191739304318210912019YFA08016032022T150012

2024

10.1016/j.fmre.2023.04.005

自然科学基础研究(英文)

自然科学基础研究(英文)

CSTPCD
ISSN：
年,卷(期)：2024.(2)
  • 22